Related references
Note: Only part of the references are listed.Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
Steffen Walter et al.
NATURE MEDICINE (2012)
Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer
P. J. Wysocki et al.
CANCER GENE THERAPY (2010)
Ten-year survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting
Matthias May et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Robert J. Amato et al.
CLINICAL CANCER RESEARCH (2010)
T regulatory cells in cancer: recent advances and therapeutic potential
Eyad Elkord et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2010)
A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic Renal Cell Carcinoma
Osama E. Rahma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN-α2a Therapy in Metastatic Renal Cell Carcinoma Patients
Thomas Schwaab et al.
CLINICAL CANCER RESEARCH (2009)
Vaccine Therapy in Patients with Renal Cell Carcinoma
Hein Van Poppel et al.
EUROPEAN UROLOGY (2009)
5T4 as a target for immunotherapy in renal cell carcinoma
Eyad Elkord et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2009)
Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α
Robert E. Hawkins et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α) A Phase 2 Trial
Robert J. Amato et al.
JOURNAL OF IMMUNOTHERAPY (2009)
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
Howard L. Kaufman et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Immune Responses in Patients with Metastatic Renal Cell Carcinoma Treated with Dendritic Cells Pulsed with Tumor Lysate
A. Soleimani et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2009)
Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma
Arkadiusz Z. Dudek et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2008)
Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
E. Jonasch et al.
BRITISH JOURNAL OF CANCER (2008)
Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial
Robert J. Amato et al.
CLINICAL CANCER RESEARCH (2008)
An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer
P. M. Patel et al.
EUROPEAN JOURNAL OF CANCER (2008)
Signaling defects in anti-tumor T cells
Alan B. Frey et al.
IMMUNOLOGICAL REVIEWS (2008)
Multiple roles for CD4(+) T cells in anti-tumor immune responses
Richard Kennedy et al.
IMMUNOLOGICAL REVIEWS (2008)
Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma
Mayer Fishman et al.
JOURNAL OF IMMUNOTHERAPY (2008)
An adjuvant autologous therapeutic vaccine (HSPPC-96 vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentrel, open-label, randomised phase III trial
Christopher Wood et al.
LANCET (2008)
Molecular origins of cancer - Cancer immunology
Olivera J. Finn
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Tumor vaccines in renal cell carcinoma
Hirotsugu Uemura et al.
WORLD JOURNAL OF UROLOGY (2008)
Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients
Shigetaka Suekane et al.
CANCER SCIENCE (2007)
Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma
Jung Han Kim et al.
CLINICAL IMMUNOLOGY (2007)
Phase I/II study of vaccination with electrofused allogeneic dendritic Cells/Autologous tumor-derived cells in patients with stage IV renal cell carcinoma
David E. Avigan et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Taking dendritic cells into medicine
Ralph M. Steinman et al.
NATURE (2007)
Immunotherapy against metastatic renal cell carcinoma with mature dendritic cells
Akihiko Matsumoto et al.
INTERNATIONAL JOURNAL OF UROLOGY (2007)
Preliminary analysis of patients with progressive renal cell carcinoma vaccinated with CA9-peptide-pulsed mature dendritic cells
Ivar Bleumer et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Immunotherapy for metastatic renal cell carcinoma: is it a therapeutic option yet?
M. Guida et al.
ANNALS OF ONCOLOGY (2007)
WT1 (Wilms' tumor 1) peptide immunotherapy for renal cell carcinoma
Tatsuo Iiyama et al.
MICROBIOLOGY AND IMMUNOLOGY (2007)
Immunotherapy of renal cell carcinoma
Cecile Gouttefangeas et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Therapeutic dendritic cell vaccination of patients with renal cell carcinoma
A Berntsen et al.
EUROPEAN UROLOGY (2006)
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
Jan Wierecky et al.
CANCER RESEARCH (2006)
A phase I trial of vaccination of CA9-derived peptides for HLA-A24-positive patients with cytokine-refractory metastatic renal cell carcinoma
H Uemura et al.
CLINICAL CANCER RESEARCH (2006)
Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
J Dannull et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide
L Höltl et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells
B Frankenberger et al.
WORLD JOURNAL OF UROLOGY (2005)
Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial
D Jocham et al.
LANCET (2004)
Autologous tumor cell line-derived vaccine for patient-specific treatment of advanced renal cell carcinoma
R Dillman et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2004)
Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study
HS Pandha et al.
BJU INTERNATIONAL (2004)
Phase I study of autologous tumor vaccines transduced with the GM-CSF gene in four patients with stage IV renal cell cancer in Japan: Clinical and immunological findings
K Tani et al.
MOLECULAR THERAPY (2004)
Immune response induced in vitro by CD16(-) and CD16(+) monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines
JC Arroyo et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2004)
A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma
BJ Gitlitz et al.
JOURNAL OF IMMUNOTHERAPY (2003)
Monoclonal antibody-based therapy for renal cell carcinoma
E Oosterwijk et al.
UROLOGIC CLINICS OF NORTH AMERICA (2003)
Allogeneic dendritic cells fused with tumor cells:: Preclinical results and outcome of a clinical phase I/II trial in patients with metastatic renal cell carcinoma
A Märten et al.
HUMAN GENE THERAPY (2003)
Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small-cell lung cancer
DEB Swinson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells:: preclinical results and outcome of a first clinical phase I/II trial
A Märten et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: A phase 1 study
JC Oosterwijk-Wakka et al.
JOURNAL OF IMMUNOTHERAPY (2002)
Cancer immunoediting: from immunosurveillance to tumor escape
GP Dunn et al.
NATURE IMMUNOLOGY (2002)
Cancer immunotherapy with peptide-based vaccines: What have we achieved? - Where are we going?
G Parmiani et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma
SJ Antonia et al.
JOURNAL OF UROLOGY (2002)
Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells:: A first clinical phase I/II trial
B Wittig et al.
HUMAN GENE THERAPY (2001)
A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon γ and human recombinant interferon α2b therapy in patients with metastatic renal cell carcinoma:: Clinical outcome and analysis of immunological parameters
T Schwaab et al.
JOURNAL OF UROLOGY (2000)